Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 1180 results for "ranbaxy"

CCI seeks public scrutiny in Sun-Ranbaxy deal probe
Money Today


[September 02, 2014] (Indian Business Insight Via Acquire Media NewsEdge) Sun Pharmaceuticals and Ranbaxy Laboratories intend to publish the details of their merger within 10 days. The Competition Commission of India had directed ... TMC Net, 12 hours ago
CCI probeS Sun-Ranbaxy deal The Statesman, 5 days ago

84 images for ranbaxy

Deccan Chronicle, 4 days ago
Business Today India, 4 days ago
Times of India, 3 days ago
NDTV, 4 days ago
India TV, 5 days ago
Deccan Chronicle, 5 days ago
Financial Express, 5 days ago
4 Traders, 5 days ago
Business Today India, 5 days ago
NDTV, 5 days ago
Times of India

RANBAXY LABORATORIES : Cci expands investigation into sun-ranbaxy deal

Sun Pharma and Ranbaxy had entered into a $4-billion deal in Apr 2014 to create the fifth largest speciality generics company in the world. The Competition Commission of India (CCI) has now directed the two companies to make public ...
 4 Traders10 hours ago CCI worried about molecular effect of Sun-Ranbaxy merger  Domain-B3 days ago CCI EXPANDS INVESTIGATION INTO SUN-RANBAXY DEAL  TMC Net10 hours ago Sun-Ranbaxy deal under CCI scanner  Times of India3 days ago

High-market concentration in some molecules is major issue in Sun Pharma-Ranbaxy deal: CCI chairman, Ashok Chawla

Capital Market September 2, 2014 Last Updated at 16:33 IST The major issue being probed in the multi-billion dollar Sun Pharma- Ranbaxy deal is to see if there is a high-market concentration in some molecules which will emerge as result of the ...
 Business Standard India10 hours ago High-market concentration major issue in Sun Pharma-Ranbaxy deal: CCI chairman  Myiris4 days ago

Buy Ranbaxy with a target of Rs 680: Prakash Gaba

In a chat with ET Now, Prakash Gaba, CFT,, shares his view on Ranbaxy. ET Now: What is your call on Ranbaxy? Prakash Gaba: Ranbaxy is a 'BUY' call with a target of Rs 680 and a stop loss of
 Economic Times13 hours ago Buy Ranbaxy with a target of Rs 589: Prakash Gaba  Economic Times3 weeks ago Buy Ranbaxy with a target of Rs 618: Sandeep Wagle  Economic Times2 weeks ago Buy Ranbaxy with a target of Rs 640: Ashwani Gujral  Economic Times2 weeks ago

Buy Ranbaxy Laboratories, says Manas Jaiswal

At 14:10 hrs Ranbaxy Laboratories was quoting at Rs 655.35, up Rs 19.95, or 3.14 percent. It has touched an intraday high of Rs 659.90 and an intraday low of
 Moneycontrol.com13 hours ago

Competition Commission of India concerned on Sun-Ranbaxy deal

Ashok Chawla New Delhi: Competition Commission of India (CCI) is scrutinising whether the $4 billion Sun-Ranbaxy deal would result in high market concentration of certain molecules. The major issues obviously are that in many of the molecules, ...
 Deccan Chronicle3 days ago CCI concerned on Sun-Ranbaxy deal  Asian Age4 days ago

RANBAXY LABORATORIES : may face another hefty fine in the US of Rs 240 crore

NEW DELHI : Ranbaxy Laboratories may have to pay another hefty fine in the United States of close to Rs 240 crore , this time imposed by the State of Texas , people familiar with the matter told ET. The company has been in negotiation with the US ...
 4 Traders5 days ago Ranbaxy Laboratories clarifies on news report  MyIris1 week ago Ranbaxy Laboratories Ltd clarifies on Rs. 242 crores fine  Equity Bulls1 week ago RANBAXY LABORATORIES : FACING Rs240 CRORE FINE IN TEXAS  4 Traders1 week ago
Business Standard

Ranbaxy hits 52-week high on UBS upgrade

MUMBAI: Shares of Ranbaxy Laboratories gained momentum for fourth consecutive session to hit 52-week high after UBS raised its target price. According to the brokerage, the stock is a cheaper way to buy Sun Pharmaceuticals. It will benefit from ...
 Economic Times1 week ago Ranbaxy hits record high, UBS raises target to Rs 784  Smart Investor1 week ago Ranbaxy hits 52-week high in volatile trade  Business Standard1 month ago Pharma shares in demand; Healthcare index hits new high  Business Standard1 month ago
Business Today India

Ranbaxy now a mid-cap stock

Until March this year, the company was part of the benchmark Nifty index Samie Modak & Joydeep Ghosh | Mumbai September 1, 2014 Last Updated at 00:29 IST Ranbaxy Laboratories, which was the country's largest pharmaceutical company in terms of FY14 ...
 Business Standard India2 days ago Adani, RCom to opt out of Nifty mid-cap  Times of India6 days ago Reliance Communications, Adani Power to Exit Nifty Midcap 50  NDTV Profit1 week ago RCom, Adani Power, Adani Enterprises to exit Nifty Midcap 50  Business Standard India1 week ago

Competition Commission of India puts Sun-Ranbaxy deal under public scrutiny

Comment · print · T T T+· T- TOPICS The deal was approved last month by leading stock exchanges BSE and NSE. The Competition Commission, which has put the multi-billion dollar Sun-Ranbaxy deal for public scrutiny, on Friday, said the ...
 The Hindu4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
Get updated on latest news & your favorite topics right in your inbox!
More     Less